These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 35973681)

  • 1. Ocular disorders associated with PCSK9 inhibitors: A pharmacovigilance disproportionality analysis.
    Zhao X; Wu J; Zhu S
    Br J Clin Pharmacol; 2023 Feb; 89(2):458-469. PubMed ID: 35973681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurocognitive Disorders Associated with PCSK9 Inhibitors: a Pharmacovigilance Disproportionality Analysis.
    Gouverneur A; Sanchez-Pena P; Veyrac G; Salem JE; Bégaud B; Bezin J
    Cardiovasc Drugs Ther; 2023 Apr; 37(2):271-276. PubMed ID: 34436707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: Data mining of the FDA adverse event reporting system.
    Ji C; Bai J; Zhou J; Zou Y; Yu M
    Br J Clin Pharmacol; 2022 Dec; 88(12):5317-5325. PubMed ID: 35818959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Ding L; Chen C; Yang Y; Fang J; Cao L; Liu Y
    Cardiovasc Ther; 2022; 2022():9866486. PubMed ID: 35140810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study.
    Goldman A; Raschi E; Cukierman-Yaffe T; Dankner R; Shouval R; Shechter M; Ben-Zvi I; Gerstein HC; Maor E
    Eur J Prev Cardiol; 2022 Jul; 29(9):1334-1342. PubMed ID: 34897409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postmarketing Reports of Incomplete Dosing-Related Complications with Self-Injected PCSK9 Inhibitors: A Descriptive Study and Disproportionality Analysis.
    Woods RH
    BioDrugs; 2024 Jul; 38(4):589-600. PubMed ID: 38874875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of Monoclonal Antibodies Inhibiting PCSK9 in Pregnancy: Disproportionality Analysis in VigiBase®.
    Noseda R; Bedussi F; Panchaud A; Ceschi A
    Clin Pharmacol Ther; 2024 Aug; 116(2):346-350. PubMed ID: 38637956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS.
    Feng Z; Li X; Tong WK; He Q; Zhu X; Xiang X; Tang Z
    Front Pharmacol; 2022; 13():894685. PubMed ID: 36506552
    [No Abstract]   [Full Text] [Related]  

  • 9. PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database.
    di Mauro G; Zinzi A; Scavone C; Mascolo A; Gaio M; Sportiello L; Ferrajolo C; Rafaniello C; Rossi F; Capuano A
    Drug Saf; 2021 Mar; 44(3):337-349. PubMed ID: 33351170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between PCSK9 inhibitors and acute kidney injury: a pharmacovigilance study.
    Liu H
    Front Pharmacol; 2024; 15():1353848. PubMed ID: 39148544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocular adverse events associated with platins: a disproportionality analysis of pharmacovigilance data and extensive systematic review of case reports.
    Hasik PN; Thomas C; Hazarika M; Undela K
    Expert Opin Drug Saf; 2024 Aug; ():1-14. PubMed ID: 39137273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychiatric disorders associated with PCSK9 inhibitors: A real-world, pharmacovigilance study.
    Deng Z; Liu J; Gong H; Cai X; Xiao H; Gao W
    CNS Neurosci Ther; 2024 Apr; 30(4):e14522. PubMed ID: 37950531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular Safety Profile of BRAF and MEK Inhibitors: Data from the World Health Organization Pharmacovigilance Database.
    Mettler C; Monnet D; Kramkimel N; Tréluyer JM; Mouthon L; Brézin A; Dupin N; Valnet-Rabier MB; Chouchana L; Terrier B
    Ophthalmology; 2021 Dec; 128(12):1748-1755. PubMed ID: 34000304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unraveling the Spectrum of Ocular Toxicity with Oxaliplatin: Clinical Feature Analysis of Cases and Pharmacovigilance Assessment of the US Food and Drug Administration Adverse Event Reporting System Database.
    Liu W; Ye X; Shan H; Wang M; Wang Y; Guo Z; Liu J; Du Q
    Clin Ther; 2024 Dec; 46(12):1049-1058. PubMed ID: 39428274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in ocular adverse events associated with phosphodiesterase-5 inhibitors: a real-world pharmacovigilance study.
    Chen G; Zhang L; Zhao ST; Huang H; Fu Z
    Expert Opin Drug Saf; 2024 Jul; 23(7):877-884. PubMed ID: 38739482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are lipid-lowering drugs associated with a risk of cataract? A pharmacovigilance study.
    Despas F; Rousseau V; Lafaurie M; De Canecaude C; Durrieu G; Bagheri H; Montastruc F; Montastruc JL
    Fundam Clin Pharmacol; 2019 Dec; 33(6):695-702. PubMed ID: 31251421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pregnancy-related adverse events associated with statins: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS).
    Wu T; Shi Y; Zhu B; Li D; Li Z; Zhao Z; Zhang Y
    Expert Opin Drug Saf; 2024 Mar; 23(3):313-321. PubMed ID: 37612600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacovigilance study of the association between tetracyclines and hepatotoxicity based on Food and Drug Administration adverse event reporting system data.
    Wei C; Liu Y; Jiang A; Wu B
    Int J Clin Pharm; 2022 Jun; 44(3):709-716. PubMed ID: 35364753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Updated Comprehensive Pharmacovigilance Study of Drug-Induced Thrombocytopenia Based on FDA Adverse Event Reporting System Data.
    Kunyu L; Shuping S; Chang S; Yiyue C; Qinyu X; Ting Z; Bin W
    J Clin Pharmacol; 2024 Apr; 64(4):478-489. PubMed ID: 38041205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.